Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 266

1.

Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study.

Tandia M, Mhiri A, Paule B, Saffroy R, Cailliez V, Noé G, Farinotti R, Bonhomme-Faivre L.

Cancer Chemother Pharmacol. 2017 Apr;79(4):759-766. doi: 10.1007/s00280-017-3268-y. Epub 2017 Mar 13.

PMID:
28289864
2.

Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid-β Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD).

Do TM, Dodacki A, Alata W, Calon F, Nicolic S, Scherrmann JM, Farinotti R, Bourasset F.

J Alzheimers Dis. 2016;49(2):287-300. doi: 10.3233/JAD-150350.

PMID:
26484906
3.

Cetuximab directly inhibits P-glycoprotein function in vitro independently of EGFR binding.

Chu C, Noël-Hudson MS, Bénard J, Ha-Duong T, Allaoui F, Farinotti R, Bonhomme-Faivre L.

Eur J Pharm Sci. 2015 Aug 30;76:18-26. doi: 10.1016/j.ejps.2015.04.014. Epub 2015 Apr 27.

PMID:
25930120
4.

Propofol, midazolam, vancomycin and cyclosporine therapeutic drug monitoring in extracorporeal membrane oxygenation circuits primed with whole human blood.

Lemaitre F, Hasni N, Leprince P, Corvol E, Belhabib G, Fillâtre P, Luyt CE, Leven C, Farinotti R, Fernandez C, Combes A.

Crit Care. 2015 Feb 12;19:40. doi: 10.1186/s13054-015-0772-5.

5.

Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide.

Goldwirt L, Beccaria K, Carpentier A, Idbaih A, Schmitt C, Levasseur C, Labussiere M, Milane A, Farinotti R, Fernandez C.

J Neurooncol. 2015 Apr;122(2):273-81. doi: 10.1007/s11060-015-1717-1. Epub 2015 Jan 13.

PMID:
25794638
6.

Irinotecan and temozolomide brain distribution: a focus on ABCB1.

Goldwirt L, Beccaria K, Carpentier A, Farinotti R, Fernandez C.

Cancer Chemother Pharmacol. 2014 Jul;74(1):185-93. doi: 10.1007/s00280-014-2490-0. Epub 2014 May 28.

PMID:
24867782
7.

Altered cerebral vascular volumes and solute transport at the blood-brain barriers of two transgenic mouse models of Alzheimer's disease.

Do TM, Alata W, Dodacki A, Traversy MT, Chacun H, Pradier L, Scherrmann JM, Farinotti R, Calon F, Bourasset F.

Neuropharmacology. 2014 Jun;81:311-7. doi: 10.1016/j.neuropharm.2014.02.010. Epub 2014 Mar 12.

PMID:
24631967
8.

Cetuximab increases concentrations of irinotecan and of its active metabolite SN-38 in plasma and tumour of human colorectal carcinoma-bearing mice.

Chu C, Abbara C, Tandia M, Polrot M, Gonin P, Farinotti R, Bonhomme-Faivre L.

Fundam Clin Pharmacol. 2014 Dec;28(6):652-60. doi: 10.1111/fcp.12071. Epub 2014 Apr 16.

PMID:
24588516
9.

Disturbed intestinal nitrogen homeostasis in a mouse model of high-fat diet-induced obesity and glucose intolerance.

Do TT, Hindlet P, Waligora-Dupriet AJ, Kapel N, Neveux N, Mignon V, Deloménie C, Farinotti R, Fève B, Buyse M.

Am J Physiol Endocrinol Metab. 2014 Mar;306(6):E668-80. doi: 10.1152/ajpendo.00437.2013. Epub 2014 Jan 14.

10.

Oatp1a4 and an L-thyroxine-sensitive transporter mediate the mouse blood-brain barrier transport of amyloid-β peptide.

Do TM, Bedussi B, Chasseigneaux S, Dodacki A, Yapo C, Chacun H, Scherrmann JM, Farinotti R, Bourasset F.

J Alzheimers Dis. 2013;36(3):555-61. doi: 10.3233/JAD-121891.

PMID:
23635403
11.

Influence of the multidrug transporter P-glycoprotein on the intracellular pharmacokinetics of vandetanib.

Jovelet C, Deroussent A, Broutin S, Paci A, Farinotti R, Bidart JM, Gil S.

Eur J Drug Metab Pharmacokinet. 2013 Sep;38(3):149-57. doi: 10.1007/s13318-013-0123-3. Epub 2013 Feb 28.

PMID:
23446814
12.

Development of a new UPLC-MSMS method for the determination of temozolomide in mice: application to plasma pharmacokinetics and brain distribution study.

Goldwirt L, Zahr N, Farinotti R, Fernandez C.

Biomed Chromatogr. 2013 Jul;27(7):889-93. doi: 10.1002/bmc.2877. Epub 2013 Feb 25.

PMID:
23436249
13.

Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms.

Lemaitre F, Bezian E, Goldwirt L, Fernandez C, Farinotti R, Varnous S, Urien S, Antignac M.

Ther Drug Monit. 2012 Dec;34(6):686-94. doi: 10.1097/FTD.0b013e318273c899.

PMID:
23131698
14.

Interferon-alpha improves docetaxel antitumoral and antimetastatic efficiency in Lewis lung carcinoma bearing mice.

Ben Reguiga M, Bouquet C, Farinotti R, Bonhomme-Faivre L.

Life Sci. 2012 Oct 29;91(17-18):843-51. doi: 10.1016/j.lfs.2012.08.027. Epub 2012 Sep 8.

PMID:
23047021
15.

[Influence of hospitalisation on drug prescription in arterial hypertension and chronic conditions].

Hindlet P, Rosenbaum D, Colpin C, Jublanc C, Farinotti R, Bruckert E, Girerd X.

Ann Cardiol Angeiol (Paris). 2012 Jun;61(3):224-8. doi: 10.1016/j.ancard.2012.06.002. Epub 2012 Jun 21. French.

PMID:
22766264
16.

Everolimus quantification in peripheral blood mononuclear cells using ultra high performance liquid chromatography tandem mass spectrometry.

Roullet-Renoleau F, Lemaitre F, Antignac M, Zahr N, Farinotti R, Fernandez C.

J Pharm Biomed Anal. 2012 Jul;66:278-81. doi: 10.1016/j.jpba.2012.03.042. Epub 2012 Mar 29.

PMID:
22571954
17.

A new UPLC-MS/MS method for the determination of irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) in mice: application to plasma and brain pharmacokinetics.

Goldwirt L, Lemaitre F, Zahr N, Farinotti R, Fernandez C.

J Pharm Biomed Anal. 2012 Jul;66:325-33. doi: 10.1016/j.jpba.2012.04.003. Epub 2012 Apr 11.

PMID:
22551773
18.

Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.

Jovelet C, Bénard J, Forestier F, Farinotti R, Bidart JM, Gil S.

Eur J Pharm Sci. 2012 Aug 15;46(5):484-91. doi: 10.1016/j.ejps.2012.03.012. Epub 2012 Mar 30.

PMID:
22484209
19.

Therapeutic efficiency of everolimus and lapatinib in xenograft model of human colorectal carcinoma with KRAS mutation.

Chu C, Noël-Hudson MS, Boige V, Goéré D, Marion S, Polrot M, Bigot L, Gonin P, Farinotti R, Bonhomme-Faivre L.

Fundam Clin Pharmacol. 2013 Aug;27(4):434-42. doi: 10.1111/j.1472-8206.2012.01035.x. Epub 2012 Mar 28.

PMID:
22458846
20.

ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1-40 at the mouse blood-brain barrier.

Do TM, Noel-Hudson MS, Ribes S, Besengez C, Smirnova M, Cisternino S, Buyse M, Calon F, Chimini G, Chacun H, Scherrmann JM, Farinotti R, Bourasset F.

J Alzheimers Dis. 2012;30(1):155-66. doi: 10.3233/JAD-2012-112189.

PMID:
22391220
21.

Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (H1N1) influenza.

Lemaitre F, Luyt CE, Roullet-Renoleau F, Nieszkowska A, Zahr N, Corvol E, Fernandez C, Antignac M, Farinotti R, Combes A.

Ther Drug Monit. 2012 Apr;34(2):171-5. doi: 10.1097/FTD.0b013e318248672c.

PMID:
22354159
22.

Rosiglitazone and metformin have opposite effects on intestinal absorption of oligopeptides via the proton-dependent PepT1 transporter.

Hindlet P, Barraud C, Boschat L, Farinotti R, Bado A, Buyse M.

Mol Pharmacol. 2012 Mar;81(3):319-27. doi: 10.1124/mol.111.073874. Epub 2011 Nov 22.

PMID:
22108913
23.

[Impact of ECMO on drugs pharmacokinetics].

Hasni N, Lemaitre F, Fernandez C, Combes A, Farinotti R.

Therapie. 2011 Sep-Oct;66(5):405-12. doi: 10.2515/therapie/2011054. Epub 2011 Oct 27. Review. French.

PMID:
22031684
24.

Direct evidence of abca1-mediated efflux of cholesterol at the mouse blood-brain barrier.

Do TM, Ouellet M, Calon F, Chimini G, Chacun H, Farinotti R, Bourasset F.

Mol Cell Biochem. 2011 Nov;357(1-2):397-404. doi: 10.1007/s11010-011-0910-6. Epub 2011 Jun 10.

PMID:
21660464
25.

Prediction tacrolimus blood levels based on the Bayesian method in adult kidney transplant patients.

Antignac M, Fernandez C, Barrou B, Roca M, Favrat JL, Urien S, Farinotti R.

Eur J Drug Metab Pharmacokinet. 2011 Mar;36(1):25-33. doi: 10.1007/s13318-011-0027-z. Epub 2011 Feb 24.

PMID:
21347736
26.

Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model.

Poissy J, Aubry A, Fernandez C, Lott MC, Chauffour A, Jarlier V, Farinotti R, Veziris N.

Antimicrob Agents Chemother. 2010 Nov;54(11):4765-71. doi: 10.1128/AAC.00968-10. Epub 2010 Aug 30.

27.

[Contributions of the ex vivo human perfused placenta in the study of placental transfer of drugs].

Ceccaldi PF, Mandelbrot L, Farinotti R, Forestier F, Gil S.

J Gynecol Obstet Biol Reprod (Paris). 2010 Dec;39(8):601-5. doi: 10.1016/j.jgyn.2010.06.010. Epub 2010 Aug 7. Review. French.

28.

Modulation of endocrine and transport functions in human trophoblasts by saquinavir and nelfinavir.

Beghin D, Forestier F, Noël-Hudson MS, Gavard L, Guibourdenche J, Farinotti R, Gil S.

Eur J Obstet Gynecol Reprod Biol. 2010 Sep;152(1):55-9. doi: 10.1016/j.ejogrb.2010.05.023. Epub 2010 Jun 29.

PMID:
20591557
29.

Oseltamivir carboxylate accumulation in a patient treated by haemodiafiltration and extracorporeal membrane oxygenation.

Lemaitre F, Luyt CE, Roullet-Renoleau F, Nieszkowska A, Zahr N, Fernandez C, Farinotti R, Combes A.

Intensive Care Med. 2010 Jul;36(7):1273-4. doi: 10.1007/s00134-010-1882-9. Epub 2010 Apr 8. No abstract available.

PMID:
20376428
30.

Cyclooxygenase-2 inhibitors prevent trinitrobenzene sulfonic acid-induced P-glycoprotein up-regulation in vitro and in vivo.

Zrieki A, Farinotti R, Buyse M.

Eur J Pharmacol. 2010 Jun 25;636(1-3):189-97. doi: 10.1016/j.ejphar.2010.03.039. Epub 2010 Mar 31.

PMID:
20361960
31.

P-glycoprotein expression and function are increased in an animal model of amyotrophic lateral sclerosis.

Milane A, Fernandez C, Dupuis L, Buyse M, Loeffler JP, Farinotti R, Meininger V, Bensimon G.

Neurosci Lett. 2010 Mar 26;472(3):166-70. doi: 10.1016/j.neulet.2010.01.078. Epub 2010 Feb 4.

PMID:
20138122
32.

Interleukin-2 treatment effect on imatinib pharmacokinetic, P-gp and BCRP expression in mice.

Hosten B, Abbara C, Cibert M, Petit B, Farinotti R, Gonin P, Bonhomme-Faivre L.

Anticancer Drugs. 2010 Feb;21(2):193-201. doi: 10.1097/CAD.0b013e3283349913.

PMID:
20016370
33.

Functional role of p-glycoprotein and binding protein effect on the placental transfer of lopinavir/ritonavir in the ex vivo human perfusion model.

Ceccaldi PF, Gavard L, Mandelbrot L, Rey E, Farinotti R, Treluyer JM, Gil S.

Obstet Gynecol Int. 2009;2009:726593. doi: 10.1155/2009/726593. Epub 2009 May 18.

34.

MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer.

Paule B, Castagne V, Picard V, Saffroy R, Adam R, Guettier C, Farinotti R, Bonhomme-Faivre L.

Med Oncol. 2010 Dec;27(4):1066-72. doi: 10.1007/s12032-009-9336-3. Epub 2009 Oct 28.

PMID:
19862647
35.

Comparative effects of drugs on P-glycoprotein expression and activity using rat and human trophoblast models.

Beghin D, Delongeas JL, Claude N, Farinotti R, Forestier F, Gil S.

Toxicol In Vitro. 2010 Mar;24(2):630-7. doi: 10.1016/j.tiv.2009.10.005. Epub 2009 Oct 17.

PMID:
19840843
36.

Contribution and limit of the model of perfused cotyledon to the study of placental transfer of drugs. Example of a protease inhibitor of HIV: nelfinavir.

Gavard L, Beghin D, Forestier F, Cayre Y, Peytavin G, Mandelbrot L, Farinotti R, Gil S.

Eur J Obstet Gynecol Reprod Biol. 2009 Dec;147(2):157-60. doi: 10.1016/j.ejogrb.2009.08.007. Epub 2009 Sep 20.

PMID:
19773109
37.

Brain and plasma riluzole pharmacokinetics: effect of minocycline combination.

Milane A, Tortolano L, Fernandez C, Bensimon G, Meininger V, Farinotti R.

J Pharm Pharm Sci. 2009;12(2):209-17.

38.

Role of two efflux proteins, ABCB1 and ABCG2 in blood-brain barrier transport of bromocriptine in a murine model of MPTP-induced dopaminergic degeneration.

Vautier S, Milane A, Fernandez C, Chacun H, Lacomblez L, Farinotti R.

J Pharm Pharm Sci. 2009;12(2):199-208.

39.

Effect of the ABCB1 3435C>T polymorphism on tacrolimus concentrations and dosage requirements in liver transplant recipients.

Bonhomme-Faivre L, Picard V, Saliba F, Abbara C, Fodil M, Chaunoy M, Farinotti R.

Am J Health Syst Pharm. 2009 Sep 15;66(18):1645-51. doi: 10.2146/ajhp080396.

PMID:
19729569
40.

Association between ABCB1 C3435T polymorphism and increased risk of cannabis dependence.

Benyamina A, Bonhomme-Faivre L, Picard V, Sabbagh A, Richard D, Blecha L, Rahioui H, Karila L, Lukasiewicz M, Farinotti R, Picard V, Marill C, Reynaud M.

Prog Neuropsychopharmacol Biol Psychiatry. 2009 Oct 1;33(7):1270-4. doi: 10.1016/j.pnpbp.2009.07.016. Epub 2009 Jul 20.

PMID:
19625010
41.

Disposition of everolimus in mdr1a-/1b- mice and after a pre-treatment of lapatinib in Swiss mice.

Chu C, Abbara C, Noël-Hudson MS, Thomas-Bourgneuf L, Gonin P, Farinotti R, Bonhomme-Faivre L.

Biochem Pharmacol. 2009 May 15;77(10):1629-34. doi: 10.1016/j.bcp.2009.02.013. Epub 2009 Mar 3.

PMID:
19426700
42.

Impact of cerebral malaria on brain distribution of mefloquine.

de Lagerie SB, Fernandez C, German-Fattal M, Gantier JC, Gimenez F, Farinotti R.

Drug Metab Lett. 2009 Jan;3(1):15-7.

PMID:
19356112
43.

Stability of oxaliplatin solution.

Junker A, Roy S, Desroches MC, Moussay C, Berhoune M, Bellanger A, Fernandez C, Farinotti R.

Ann Pharmacother. 2009 Feb;43(2):390-1. doi: 10.1345/aph.1L122. Epub 2009 Feb 3. No abstract available.

PMID:
19193594
44.

Interactions between riluzole and ABCG2/BCRP transporter.

Milane A, Vautier S, Chacun H, Meininger V, Bensimon G, Farinotti R, Fernandez C.

Neurosci Lett. 2009 Mar 6;452(1):12-6. doi: 10.1016/j.neulet.2008.12.061. Epub 2009 Jan 6.

PMID:
19146924
45.

Reduced intestinal absorption of dipeptides via PepT1 in mice with diet-induced obesity is associated with leptin receptor down-regulation.

Hindlet P, Bado A, Kamenicky P, Deloménie C, Bourasset F, Nazaret C, Farinotti R, Buyse M.

J Biol Chem. 2009 Mar 13;284(11):6801-8. doi: 10.1074/jbc.M805564200. Epub 2009 Jan 14.

46.

Combination of tenofovir and emtricitabine plus efavirenz: in vitro modulation of ABC transporter and intracellular drug accumulation.

Bousquet L, Pruvost A, Guyot AC, Farinotti R, Mabondzo A.

Antimicrob Agents Chemother. 2009 Mar;53(3):896-902. doi: 10.1128/AAC.00733-08. Epub 2008 Dec 15.

47.

Development and characterisation of a new model of rat trophoblasts.

Beghin D, Delongeas JL, Claude N, Forestier F, Farinotti R, Gil S.

Toxicol In Vitro. 2009 Feb;23(1):141-7. doi: 10.1016/j.tiv.2008.10.007. Epub 2008 Oct 25.

PMID:
19013229
48.

MDR1A (ABCB1)-deficient CF-1 mutant mice are susceptible to cerebral malaria induced by Plasmodium berghei ANKA.

de Lagerie SB, Fernandez C, German-Fattal M, Gantier JC, Gimenez F, Farinotti R.

J Parasitol. 2008 Oct;94(5):1139-42. doi: 10.1645/GE-1493.1.

PMID:
18973419
49.

Effect of oil-in-water submicron emulsion surface charge on oral absorption of a poorly water-soluble drug in rats.

Poullain-Termeau S, Crauste-Manciet S, Brossard D, Muhamed S, Nicolaos G, Farinotti R, Barthélémy C, Robert H, Odou P.

Drug Deliv. 2008 Nov;15(8):503-14. doi: 10.1080/10717540802321792 .

PMID:
18923979
50.

Comparison of ABC transporter modulation by atazanavir in lymphocytes and human brain endothelial cells: ABC transporters are involved in the atazanavir-limited passage across an in vitro human model of the blood-brain barrier.

Bousquet L, Roucairol C, Hembury A, Nevers MC, Creminon C, Farinotti R, Mabondzo A.

AIDS Res Hum Retroviruses. 2008 Sep;24(9):1147-54. doi: 10.1089/aid.2007.0022.

PMID:
18729774

Supplemental Content

Loading ...
Support Center